Clinical Farmacology
Vol. 2 No. 3 (2008)
Low doses of terlipressin and albumin in the type I hepatorenal syndrome
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 2 May 2013
Accepted: 2 May 2013
Accepted: 2 May 2013
908
Views
6024
Downloads
Authors
MATERIALS AND METHODS We investigated the improvement of renal function in subjects with hepatorenal syndrome after terlipressin administration and the survival times after this treatment. 30 patients affected by cirrhosis, with diagnosis of type I hepatorenal syndrome were treated with intravenous terlipressin plus albumin (group A) or with albumin alone (group B). Liver function, renal function, sodium plasma level and plasma renin activity were monitored.
RESULTS Patients of group A showed a significant improvement (p < 0.001) of renal function valued by creatinine rate compared with the results obtained in group B. The probability of survival was higher in the group A (p < 0.0001).
CONCLUSIONS Our results seem to confirm that the administration of terlipressin plus albumin improves renal function in patients with cirrhosis and type I hepatorenal syndrome and that a reversal of hepatorenal syndrome is strongly associated with an improved survival.
Downloads
Download data is not yet available.
Citations
How to Cite
Low doses of terlipressin and albumin in the type I hepatorenal syndrome. (2013). Italian Journal of Medicine, 2(3), 34-38. https://doi.org/10.4081/itjm.2008.3.34